The association between Interleukin-6 and C-Reactive Protein in Covid-19 patients
DOI:
https://doi.org/10.54957/ijhs.v6i4.2383Kata Kunci:
Biomarkers, Covid-19, C-Reactive Protein, Cytokine Storm, Inflammation, Interleukin-6Abstrak
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is characterized by an excessive inflammatory response that may lead to cytokine storm and worsening clinical outcomes. Interleukin-6 (IL-6) is a major pro-inflammatory cytokine that stimulates the production of C-reactive protein (CRP), making both biomarkers useful for assessing the inflammatory response in patients with COVID-19. Objective: This study aimed to determine the association between serum IL-6 and CRP levels in patients with COVID-19. Methods: This retrospective observational study analyzed medical record data from 30 patients with COVID-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR). Serum IL-6 and CRP levels were obtained from laboratory results recorded in hospital medical records. Statistical analysis was performed using IBM SPSS Statistics version 22. The association between serum IL-6 levels as the independent variable and CRP levels as the dependent variable was assessed using simple linear regression analysis. The results were reported as the regression coefficient (β), correlation coefficient (R), coefficient of determination (R²), and p-value. Results: Simple linear regression analysis demonstrated a significant positive association between serum IL-6 and CRP levels (β = 0.335; R = 0.538; R² = 0.290; p = 0.002). The positive regression coefficient indicated that higher serum IL-6 levels were associated with higher CRP levels. The R² value indicated that serum IL-6 explained 29.0% of the variation in CRP levels. Elevated IL-6 and CRP levels were observed in 90% and 93% of patients, respectively. Conclusion: Serum IL-6 levels were significantly and positively associated with CRP levels in patients with COVID-19. These findings suggest that IL-6 and CRP may provide complementary information for assessing the inflammatory response in patients with COVID-19.
Referensi
Aziz, M., Fatima, R., & Assaly, R. (2020). Elevated interleukin-6 and severe COVID-19: A meta-analysis. Journal of Medical Virology, 92 (11), 2283–2285. https://doi.org/10.1002/jmv.25948
Callaway, E. (2020). The race for coronavirus vaccines: A graphical guide. Nature, 580 (7805), 576–577. https://doi.org/10.1038/d41586-020-01221-y
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 130(5), 2620–2629. https://doi.org/10.1172/JCI137244
Coomes, E. A., & Haghbayan, H. (2020). Interleukin-6 in COVID-19: A systematic review and meta-analysis. Reviews in Medical Virology, 30 (6), e2141. https://doi.org/10.1002/rmv.2141
Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., Marron, T. U., Xie, H., Patel, M., Tuballes, K., Van Oekelen, O., Rahman, A., Kovatch, P., Aberg, J. A., Schadt, E., Gnjatic, S. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 26 (10), 1636–1643. https://doi.org/10.1038/s41591-020-1051-9
Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., Vilahur, G., Badimon, L., ten Berg, J. M., ten Cate, H., Peyvandi, F., Wang, T. T. Becker, R. C. (2022). Current and novel biomarkers of thrombotic risk in COVID-19: A consensus statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 19 (7), 475–495. https://doi.org/10.1038/s41569-021-00665-7
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020). Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 146 (1), 128–136.e4. https://doi.org/10.1016/j.jaci.2020.05.008
Jones, S. A., & Hunter, C. A. (2021). Is IL-6 a key cytokine target for therapy in COVID-19? Nature Reviews Immunology, 21 (6), 337–339. https://doi.org/10.1038/s41577-021-00553-3
Kishimoto, T., & Kang, S. (2022). IL-6 revisited: From rheumatoid arthritis to CAR T cell therapy and COVID-19. Annual Review of Immunology, 40, 323–348. https://doi.org/10.1146/annurev-immunol-101220-023856
Korsman, S. N. J., van Zyl, G. U., Nutt, L., & Andersson, M. I. (2020). Virology. Churchill Livingstone Elsevier.
Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., Li, B., Song, X., & Zhou, X. (2020). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology, 127, 104370. https://doi.org/10.1016/j.jcv.2020.104370
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2020). A linear prognostic score based on IL-6 and CRP predicts outcomes in COVID-19. EBioMedicine, 61, 103026. https://doi.org/10.1016/j.ebiom.2020.103026
Moore, J. B., & June, C. H. (2020). Cytokine release syndrome in severe COVID-19. Science, 368 (6490), 473–474. https://doi.org/10.1126/science.abb8925
Perhimpunan Dokter Paru Indonesia. (2020). Panduan praktik klinis: Pneumonia 2019-nCoV. PDPI.
Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., & Salem, R. (2020). The COVID-19 cytokine storm: What we know so far. Frontiers in Immunology, 11, 1446. https://doi.org/10.3389/fimmu.2020.01446
Samprathi, M., & Jayashree, M. (2021). Biomarkers in COVID-19: An up-to-date review. Frontiers in Pediatrics, 8, 607647. https://doi.org/10.3389/fped.2020.607647
Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., Capela, C., Pedrosa, J., Castro, A. G., & Silvestre, R. (2021). Interleukin-6 is a biomarker for the development of fatal SARS-CoV-2 pneumonia. Frontiers in Immunology, 12, 613422. https://doi.org/10.3389/fimmu.2021.613422
Schett, G., Sticherling, M., & Neurath, M. F. (2020). How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nature Reviews Rheumatology, 16 (8), 465–470. https://doi.org/10.1038/s41584-020-0440-3
Sproston, N. R., & Ashworth, J. J. (2018). Role of C-reactive protein at sites of inflammation and infection. Frontiers in Immunology, 9, 754. https://doi.org/10.3389/fimmu.2018.00754
Stringer, D., Braude, P., Myint, P. K., Evans, L., Collins, J. T., Verduri, A., Quinn, T. J., Vilches-Moraga, A., Stechman, M., Pearce, L., McCarthy, K., Hewitt, J., Carter, B., & COPE Study Collaborators. (2021). C-reactive protein and prognostic outcomes in COVID-19: A systematic review and meta-analysis. Frontiers in Immunology, 12, 720363. https://doi.org/10.3389/fimmu.2021.720363
Wang, Z., Scheet, R., & Qiang, W. (2020). A handbook of 2019-nCoV pneumonia control and prevention. Hubei Science and Technology Press.
World Health Organization. (2020). WHO Director-General's remarks at the media briefing on 2019-nCoV. https://www.who.int/director-general/speeches
Zhong, J., Tang, J., Ye, C., & Dong, L. (2020). The immunology of COVID-19: Is immune modulation an option for treatment. The Lancet Rheumatology, 2 (7), e428–e436. https://doi.org/10.1016/S2665-9913(20)30120-X
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2026 Cici Nuriah, Anang Rizky Maulana, Faradiyan Kencana
Artikel ini berlisensi Creative Commons Attribution 4.0 International License.
